Arvinas Inc.

Quick facts

Phase 1 pipeline

• ARV-110 · Oncology
  Selective androgen receptor degrader
• ARV-393
• ARV-806 · Oncology
  ARV-806 is a PROTAC (proteolysis targeting chimera) designed to degrade the androgen receptor (AR) in prostate cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Arvinas Inc. portfolio CI brief
• Arvinas Inc. pipeline updates RSS